VICL (Vical Labs) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	9/15/2010 11:53:25 AM
	of 1972

Needham Company Reiterates a 'Buy' on Vical, Inc. (VICL); Encouraging Phase 2 TransVax Data Presented at ICAAC Needham Company reiterates a 'Buy' rating on Vical, Inc. (Nasdaq: VICL), PT $8. Needham analyst says, "Vical presented final results of the 1-year Phase 2 TransVax trial in CMV at the ICAAC meeting yesterday. The vaccine had a statistically significant impact on several viral parameters...Overall, the results add to the credibility of DNA vaccines/ therapeutics. We believe there is room for upside to the stock later this fall, particularly with the upcoming release of Phase 3 Temusi trial results in Critical Limb Ischemia by collaborator sanofi (NYSE: SNY)."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next